Abstract:

 Proliferative diabetic retinopathy (PDR) is the leading cause of diabetic blindness. At present, panretinal photocoagulation (PRP) is the standard treatment for PDR, however it can cause side effects, such as increasing risk of macular edema, or decreasing peripheral vision. Anti-vascular endothelial growth factor (VEGF) therapy shows the possibility of treatment as a substitution for PRP: intrvitreal anti-VEGF agent can effectively clear intraocular VEGF, cause regression of new vessels, and improve retinopathy severity.  It may improve the prognosis of PDR to explore the module and methods of combination of PRP and anti-VEGF therapy.

Key words: diabetic retinopathy, panretinal photocoagulation, anti-vascular epithelial growth factor